Cara Therapeutics | CARA - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
Cara Therapeutics USD 7.05M 1.11M 2026-03
Cassava Sciences USD 11.17M 2.38M 2026-03
Chugai Pharma JPY 180.73B 17.74B 2026-06
Cipla INR 62.31B 3.04B 2026-06
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 11.19M 96K 2026-03
CSL USD 5.7B 2.82B 2025-12
Grifols EUR 1.99B 217.4M 2025-12
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
J&J USD 17.83B 388M 2026-06
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Pacira USD 180.54M 7.79M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
RedHill Biopharma USD 5.51M 1.08M 2024-06
Supernus Pharmaceuticals USD 1.03B 45.58M 2026-06
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12